6.1.2026 08:52:15 CET | Thor Medical ASA | Mandatory notification of trade
primary insiders

6 January 2026 | Thor Medical ASA | Mandatory notification of trade primary
insiders

The Board of Directors of Thor Medical ASA (the "Company") has decided to award
Chief Technology Officer Prof. Sindre Hassfjell a cash bonus, subject to the net
bonus after taxes being invested in shares in the Company.

The award is made in recognition of Prof. Hassfjell's significant contributions,
to date and going forward, to the Company's intellectual property portfolio.

The Board of Directors has in connection with the bonus award issued 63,739
shares to Prof. Hassfjell. The subscription price for each share has been set to
the volume-weighted average trading price (VWAP) of the Company's shares on Oslo
Stock Exchange during the 10 trading days immediately preceding the date of the
award, being NOK 4.95. The shares are subject to lock-up until the end of 2027.
The bonus award is further subject to customary terms and conditions for
employee incentive programs.

Following the issuance and delivery of the new shares, Prof. Hassfjell holds and
controls 143,739 shares and 2,700,000 share options in the Company.

The Company's existing shareholder's pre-emptive rights to subscribe for shares
is set aside in consideration of the purpose of the incentive program and the
share capital increase.

Upon completion of the issuance of shares, the Company's share capital will be
increased with a total of NOK 12,748, by issuing 63,739 new shares. After
completion, the share capital of Thor Medical ASA will be NOK 70,844,127 divided
on 354,220,633 shares, each with a nominal value of NOK 0.20.

Notification of the transaction in accordance with the Market Abuse Regulation
Article 19 is attached to this announcement.

CONTACTS

John Andersen, Jr., Chair of the Board of Directors, +47 90 17 40 80, 
john.andersen@scatec.no

ABOUT THOR MEDICAL ASA

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

To learn more, visit www.thormedical.com - http://www.thormedical.com - 
https://www.thormedical.com.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18765643/6674/Download%20announce
ment%20as%20PDF.pdf

Skjema for melding om transaksjoner av personer med ledelsesansvar KRT-1500.pdf
-
https://kommunikasjon.ntb.no/ir-files/17848634/18765643/6673/Skjema%20for%20meld
ing%20om%20transaksjoner%20av%20personer%20med%20ledelsesansvar%20KRT-1500.pdf